These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 19281600)

  • 41. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
    de Leon J; Dinsmore L; Wedlund P
    J Clin Psychopharmacol; 2003 Aug; 23(4):420-1. PubMed ID: 12920424
    [No Abstract]   [Full Text] [Related]  

  • 42. Polymorphism of dextromethorphan oxidation in Polish population.
    Skretkowicz J; Wojtczak A; Rychlik-Sych M
    Acta Pol Pharm; 2008; 65(5):611-5. PubMed ID: 19051610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.
    Klimas R; Witticke D; El Fallah S; Mikus G
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):517-28. PubMed ID: 23488585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Morphine or oxycodone in cancer pain?
    Heiskanen TE; Ruismäki PM; Seppälä TA; Kalso EA
    Acta Oncol; 2000; 39(8):941-7. PubMed ID: 11207001
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
    Halling J; Weihe P; Brosen K
    Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients.
    Yee DA; Best BM; Atayee RS; Pesce AJ
    J Anal Toxicol; 2012 May; 36(4):232-8. PubMed ID: 22511697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.
    Babalonis S; Lofwall MR; Nuzzo PA; Walsh SL
    Addict Biol; 2016 Jan; 21(1):146-58. PubMed ID: 25130052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction.
    Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
    J Clin Pharmacol; 2010 Feb; 50(2):214-25. PubMed ID: 19948945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduction of human experimental muscle pain by alfentanil and morphine.
    Schulte H; Segerdahl M; Graven-Nielsen T; Grass S
    Eur J Pain; 2006 Nov; 10(8):733-41. PubMed ID: 16414295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
    Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
    J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone.
    Beaver WT; Wallenstein SL; Rogers A; Houde RW
    J Pharmacol Exp Ther; 1978 Oct; 207(1):92-100. PubMed ID: 359779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
    Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
    J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
    Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
    Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Observations of urinary oxycodone and metabolite distributions in pain patients.
    Elder NM; Atayee RS; Best BM; Ma JD
    J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complicated pain management in a CYP450 2D6 poor metabolizer.
    Foster A; Mobley E; Wang Z
    Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
    Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
    Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study.
    Olesen AE; Staahl C; Arendt-Nielsen L; Drewes AM
    Br J Clin Pharmacol; 2010 Aug; 70(2):189-200. PubMed ID: 20653672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acetaminophen reinforces descending inhibitory pain pathways.
    Pickering G; Estève V; Loriot MA; Eschalier A; Dubray C
    Clin Pharmacol Ther; 2008 Jul; 84(1):47-51. PubMed ID: 17957182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxycodone findings and CYP2D6 function in postmortem cases.
    Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
    Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.